Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) EBT Margin (2021 - 2023)

Senti Biosciences has reported EBT Margin over the past 3 years, most recently at 12808.58% for Q3 2023.

  • Quarterly results put EBT Margin at 12808.58% for Q3 2023, down 1187151.0% from a year ago — trailing twelve months through Jun 2024 was 26821.01% (down 2518152.0% YoY), and the annual figure for FY2025 was 308418.18%, changed.
  • EBT Margin for Q3 2023 was 12808.58% at Senti Biosciences, down from 2095.2% in the prior quarter.
  • Over the last five years, EBT Margin for SNTI hit a ceiling of 937.07% in Q3 2022 and a floor of 26552.54% in Q4 2022.
  • Median EBT Margin over the past 3 years was 1213.6% (2021), compared with a mean of 5008.49%.
  • Peak annual rise in EBT Margin hit 29597bps in 2022, while the deepest fall reached -2535840bps in 2022.
  • Senti Biosciences' EBT Margin stood at 1194.14% in 2021, then tumbled by -2124bps to 26552.54% in 2022, then soared by 52bps to 12808.58% in 2023.
  • The last three reported values for EBT Margin were 12808.58% (Q3 2023), 2095.2% (Q2 2023), and 1081.1% (Q1 2023) per Business Quant data.